{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.2","upperLimit":"7.3","value":"6.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"DOR is defined as the time from date of first documented confirmed objective response to date of first documented progressive disease (PD). Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated.","dispersionType":"Full Range","groups":[{"description":"Participants will receive:\n\nPembrolizumab 200 mg IV on Day 1 of each 21-day cycle (±3 days) for Cycles 1 and 2 (lead-in therapy).\n\n9-ING-41 administered twice per 21-day cycle on Day 1 and Day 4 for up to 1 year. Treatment with 9-ING-41 may continue beyond 1 year in participants with ongoing clinical benefit.\n\nCarboplatin administered once per 21-day cycle on Day 1 for up to 1 year.","id":"OG000","title":"Pembrolizumab + 9-ING-41 + Carboplatin (Part II)"}],"paramType":"MEDIAN","populationDescription":"Arms are defined by treatment assignment. Adenoid cystic carcinoma (ACC) and non-ACC represent disease subgroups within each treatment arm and were not assigned to separate treatment arms. Therefore, participants are reported according to treatment assignment rather than histologic subtype. The analysis dataset is comprised of all participants with measurable disease at baseline who achieved objective response on treatment. No responders among Part I participants.","reportingStatus":"POSTED","timeFrame":"Tumor assessments were performed every 3 cycles (each cycle was 21 days), for up to 15.6 months.","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}